文献速递妇科

VIGI-MESH登记中2682例患者经耻骨后与经闭孔中段尿道吊带术后的严重并发症与复发再手术比较

Serious complications and recurrences after retropubic vs transobturator midurethral sling procedures for 2682 patients in the VIGI-MESH register.
PubMed 文献 · Am J Obstet Gynecol · 2023-11-25

基于法国多中心VIGI-MESH登记(2017年2月起,随访至2021年10月),比较经耻骨后与经闭孔途径中段尿道吊带术的严重并发症和复发再手术。1830例经耻骨后、852例经闭孔,经倾向评分加权和Cox模型分析,经闭孔途径严重并发症风险更低(调整HR 0.41),但复发再手术风险更高(调整HR 1.9),排除既往抗尿失禁手术后该超额风险消失。

要点

  • 经闭孔途径严重并发症风险约为经耻骨后途径的一半(调整HR 0.41)。
  • 经闭孔途径复发再手术风险约为经耻骨后途径的1.9倍(调整HR 1.9)。
  • 排除既往抗尿失禁手术后,经闭孔途径再手术超额风险消失。

核心结论

  • 经闭孔途径中段尿道吊带术的严重并发症风险低于经耻骨后途径,但复发再手术风险高于经耻骨后途径。
  • 尽管参与外科医生数量多,上述风险均较低,数据令人安心。

研究设计与样本

  • 基于法国多中心VIGI-MESH登记的分析,纳入2017年2月起接受中段尿道吊带术的女性压力性尿失禁患者,排除单切口吊带,随访至2021年10月。
  • 共1830例经耻骨后、852例经闭孔,由27个法国中心的167名外科医生放置。
  • 采用Cox比例风险模型比较严重并发症(Clavien-Dindo分级≥III级)和复发再手术,模型纳入相关手术(子宫切除或脱垂)和中心效应的脆弱项,并用倾向评分加权平衡基线差异。

主要发现

  • 严重并发症2年累积估计:经耻骨后组5.8%(95%CI 4.8-7.0),经闭孔组2.9%(95%CI 1.9-4.3);调整后经闭孔组风险约为经耻骨后组的一半(调整HR 0.41;95%CI 0.3-0.6)。
  • 压力性尿失禁复发再手术2年累积估计:经耻骨后组2.7%(95%CI 2.0-3.6),经闭孔组2.8%(95%CI 1.7-4.2);调整后经闭孔组复发再手术风险更高(调整HR 1.9;95%CI 1.2-2.9)。
  • 排除既往因压力性尿失禁手术的患者后,经闭孔组的再手术超额风险消失。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Midurethral slings are the gold standard for treating stress urinary incontinence, but their complications may raise concerns. Complications may differ by the approach used to place them. OBJECTIVE: This study aimed to compare serious complications and reoperations for recurrence after midurethral sling procedures when using the retropubic vs the transobturator route for female stress urinary incontinence. STUDY DESIGN: This analysis was of patients included in the French, multicenter VIGI-MESH register since February 2017 who received a midurethral sling for female stress urinary incontinence either by the retropubic or the transobturator route and excluded patients with single-incision slings. Follow-up continued until October 2021. Serious complications (Clavien-Dindo classification ≥ grade III) attributable to the midurethral sling and reoperations for recurrence were compared using Cox proportional hazard models including any associated surgery (hysterectomy or prolapse) and a frailty term to consider the center effect. Baseline differences were balanced by propensity score weighting. Analyses using the propensity score and Cox models were adjusted for baseline differences, center effect, and associated surgery. RESULTS: A total of 1830 participants received a retropubic sling and 852 received a transobturator sling in 27 French centers that were placed by 167 surgeons. The cumulative 2-year estimate of serious complications was 5.8% (95% confidence interval, 4.8-7.0) in the retropubic group and 2.9% (95% confidence interval, 1.9-4.3) in the transobturator group, that is, after adjustment, half of the retropubic group was affected (adjusted hazard ratio, 0.41; 95% confidence interval, 0.3-0.6). The cumulative 2-year estimate of reoperation for recurrence of stress urinary incontinence was 2.7% (95% confidence interval, 2.0-3.6) in the retropubic group and 2.8% (95% confidence interval, 1.7-4.2) in the transobturator group with risk for revision for recurrence being higher in the transobturator group after adjustment (adjusted hazard ratio, 1.9; 95% confidence interval, 1.2-2.9); this surplus risk disappeared after exclusion of the patients with a previous surgery for stress urinary incontinence. CONCLUSION: The transobturator route for midurethral sling placement is associated with a lower risk for serious complications but a higher risk for surgical reoperation for recurrence than the retropubic route. Despite the large number of surgeons involved, these risks were low. The data are therefore reassuring.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Armengaud C, Fauconnier A, Drioueche H, et al. Serious complications and recurrences after retropubic vs transobturator midurethral sling procedures for 2682 patients in the VIGI-MESH register. Am J Obstet Gynecol. 2023. PMID: 38008151. doi:10.1016/j.ajog.2023.11.1241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。